Immune aging and drug discovery
LinkedIn caption
🧬 Immune aging and drug discovery
At ARDD 2026, Christopher Austin of GSK discussed aging as a set of unifying biological principles, with immune aging and inflammaging especially relevant to therapeutic development. The official recap highlights fibroinflammatory disease across several organs among the potential first indications.
💡 His partnering-panel contribution also connected that biology with disciplined use of AI: controlled environments for data and models, alongside caution about unsupported longevity-company valuations. The opportunity is substantial, and credible disease-specific evidence remains central to translating it into medicines.
#ARDD2026 #DrugDiscovery
X caption
🧬 Christopher Austin of GSK connected immune aging and inflammaging with drug discovery at #ARDD2026, highlighting disease-specific evidence and controlled AI/data environments as foundations for credible partnerships. The first indication needs a clear clinical rationale.
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
